GGrantIndex
← Leaderboards

Scott D Ramsey

Fred Hutchinson Cancer Research Center

Google Scholar ↗PubMed ↗ORCID ↗
$15,774,676
Attributed
$25,321,593
Total exposure
13
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $9.2M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$25,321,593 · 13

By mechanism

UG1$9,936,485 · 2
R01$7,182,238 · 5
U01$2,567,960 · 1
RC2$2,041,110 · 1
UC2$1,958,890 · 1
OT3$727,500 · 1

Top collaborators

Most similar at Fred Hutchinson Cancer Research Center

Same institution · by research overlap

Others in their field

Top investigators on “Resources”

Research focus

ResourcesCostRecordsMalignant NeoplasmsCaringDesignEvaluationProviderSurveysEconomicsDiagnosisStructureLinkCost EffectivenessInterestProgramsCohortCancer CareCommunitiesCancer TherapyPoliciesCost Effectiveness AnalysisNational Cancer InstituteModels And Simulation

Grant awards (40)

NCI Cancer Screening Research Network: Coordinating and Communication Center$5,483,979
UG1 · FY2025 · CA
The Pacific Cancer Research Consortium (PCRC), an NCORP Community Site$2,706,333
UG1 · FY2025 · CA
NCI Cancer Screening Research Network: Coordinating and Communication Center$616,000
UG1 · FY2025 · CA
Financial and Clinical Outcomes among Commercially-Insured Cancer Patients following the Affordable Care Act$402,600
R01 · FY2025 · CA · contact PI
NCI Cancer Screening Research Network: Coordinating and Communication Center$1,130,173
UG1 · FY2024 · CA
Disparities in Financial and Clinical Outcomes among Commercially-Insured Cancer Patients following the Affordable Care Act$402,600
R01 · FY2024 · CA · contact PI
The Cure Sickle Cell Initiative Economic Analysis: An Evaluation of the Costs of Sickle Cell Disease and Potential Health Plan Budget Impacts of Gene Therapy as a New Treatment Option$390,634
OT3 · FY2019 · HL · contact PI
The Cure Sickle Cell Initiative Economic Analysis: An Evaluation of the Costs of Sickle Cell Disease and Potential Health Plan Budget Impacts of Gene Therapy as a New Treatment Option$336,866
OT3 · FY2019 · HL · contact PI
Cost Effectiveness Analysis of Stem Cell Transplant in Older MDS Patients$432,375
R01 · FY2018 · HL · contact PI
Cost Effectiveness Analysis of Stem Cell Transplant in Older MDS Patients$432,539
R01 · FY2017 · HL · contact PI
OPTIMIZING PERSONALIZED CARE USING ECONOMIC STUDIES OF GENOMIC TESTING$426,812
U01 · FY2017 · CA
Cost Effectiveness Analysis of Stem Cell Transplant in Older MDS Patients$438,455
R01 · FY2016 · HL · contact PI
OPTIMIZING PERSONALIZED CARE USING ECONOMIC STUDIES OF GENOMIC TESTING$430,454
U01 · FY2016 · CA
OPTIMIZING PERSONALIZED CARE USING ECONOMIC STUDIES OF GENOMIC TESTING$124,854
U01 · FY2016 · CA
BMT CTN 1101 Ancillary Cost-Effectiveness Analysis$433,400
R01 · FY2015 · HL · contact PI
OPTIMIZING PERSONALIZED CARE USING ECONOMIC STUDIES OF GENOMIC TESTING$431,794
U01 · FY2015 · CA
Cost Effectiveness Analysis of Stem Cell Transplant in Older MDS Patients$421,094
R01 · FY2015 · HL · contact PI
Optimizing Personalized Care Using Economic Studies of Genomic Testing: Supporting Patient-Provider$138,291
U01 · FY2015 · CA
OPTIMIZING PERSONALIZED CARE USING ECONOMIC STUDIES OF GENOMIC TESTING$442,902
U01 · FY2014 · CA
BMT CTN 1101 Ancillary Cost-Effectiveness Analysis$431,200
R01 · FY2014 · HL · contact PI
OPTIMIZING PERSONALIZED CARE USING ECONOMIC STUDIES OF GENOMIC TESTING$139,021
U01 · FY2014 · CA
OPTIMIZING PERSONALIZED CARE USING ECONOMIC STUDIES OF GENOMIC TESTING$433,832
U01 · FY2013 · CA
BMT CTN 1101 Ancillary Cost-Effectiveness Analysis$418,880
R01 · FY2013 · HL · contact PI
BMT CTN 1101 Ancillary Cost-Effectiveness Analysis$440,000
R01 · FY2012 · HL · contact PI
A Multi-State Study of Cancer Treatment and Outcomes Among American Indians$374,097
R01 · FY2012 · CA · contact PI
A Multi-State Study of Cancer Treatment and Outcomes Among American Indians$284,400
R01 · FY2011 · CA · contact PI
Center for Comparative Effectiveness Research in Cancer Genomics - CANCERGEN$1,958,890
UC2 · FY2010 · CA · contact PI
A Multi-State Study of Cancer Treatment and Outcomes Among American Indians$286,758
R01 · FY2010 · CA · contact PI
A Study of Cancer Diagnosis as a Risk Factor for Personal Bankruptcy$264,026
RC1 · FY2010 · MD · contact PI
Center for Comparative Effectiveness Research in Cancer Genomics - CANCERGEN$2,041,110
RC2 · FY2009 · CA · contact PI
A Study of Cancer Diagnosis as a Risk Factor for Personal Bankruptcy$231,574
RC1 · FY2009 · MD · contact PI
A Multi-State Study of Cancer Treatment and Outcomes Among American Indians$426,676
R01 · FY2008 · CA · contact PI
A Multi-State Study of Cancer Treatment and Outcomes Among American Indians$552,813
R01 · FY2007 · CA · contact PI
A Genetic Screening Policy Model for Colorectal Cancer$398,025
R01 · FY2006 · CA · contact PI
A Genetic Screening Policy Model for Colorectal Cancer$284,015
R01 · FY2005 · CA
A Genetic Screening Policy Model for Colorectal Cancer$322,311
R01 · FY2004 · CA
COST EFFECTIVENESS OF GENETIC SCREENING FOR COLON CANCER$145,467
K01 · FY2002 · CA
COST EFFECTIVENESS OF GENETIC SCREENING FOR COLON CANCER$148,082
K01 · FY2001 · CA
COST EFFECTIVENESS OF GENETIC SCREENING FOR COLON CANCER$92,799
K01 · FY2000 · CA
COST EFFECTIVENESS OF GENETIC SCREENING FOR COLON CANCER$25,462
K01 · FY2000 · CA